Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety

Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight

Piramal Pharma Solutions’ UK facility bags updated MHRA GMP certification

Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub

Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12

Piramal Pharma Solutions supports George Medicines in developing new drug for hypertension

WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals

Piramal Pharma Solutions opens dedicated OSD production capabilities at Sellersville, Pennsylvania site

The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities

Piramal Pharma Solutions announces US$ 80 million expansion plan for Sterile Injectables facility in Kentucky

Piramal Pharma Solutions commissions ADC manufacturing expansion in Scotland

The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant

Piramal Pharma Solutions launches ADCelerate

ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission

Piramal Pharma Solutions holds opening ceremony for new API Plant at Aurora, Canada

Plant is part of the company's CAD $30 million capital investment in the site

Piramal Pharma Solutions appoints Herve Berdou as COO

Brings 25 years of global operations and supply chain experience to Piramal